Multiple endocrine neoplasia type 2 prevention

Jump to navigation Jump to search

Multiple endocrine neoplasia type 2 Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple endocrine neoplasia type 2 from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History & Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Multiple endocrine neoplasia type 2 prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple endocrine neoplasia type 2 prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple endocrine neoplasia type 2 prevention

CDC on Multiple endocrine neoplasia type 2 prevention

Multiple endocrine neoplasia type 2 prevention in the news

Blogs on Multiple endocrine neoplasia type 2 prevention

Directions to Hospitals Treating Multiple endocrine neoplasia type 2

Risk calculators and risk factors for Multiple endocrine neoplasia type 2 prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

According to the American Society of Clinical Oncology, surveillance for multiple endocrine neoplasia type 2 by annual measurement of serum calcitonin, serum calcium, serum parathyroid hormone, and catacholamines is recommended postsurgically to monitor for recurrence and complications for multiple endocrine neoplasia type 2.

Secondary Prevention

Surveillance of multiple endocrine neoplasia type 2
Serum calcium level annually for people diagnosed with multiple endocrine neoplasia type 2A
Recurrent or residual medullary thyroid cancer post thyroidectomy is detected by measurement of serum calcitonin annually
Catacholamines, epinephrine and norepinephrine yearly for multiple endocrine neoplasia type 2A and multiple endocrine neoplasia type 2B patients to detect pheochromocytoma
Magnetic resonance imaging and computerized tomography for pheochromocytoma every 2-4 years
Parathyroid hormone level yearly for multiple endocrine neoplasia type 2A to detect hypoparathyroidism
Adapted from Marquard J, Eng C. Multiple Endocrine Neoplasia Type 2. 1999 Sep 27 [Updated 2015 Jun 25]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2015. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1257/[1]











References

  1. Jessica Marquard & Charis Eng (1993). "Multiple Endocrine Neoplasia Type 2". PMID 020301434.

Template:WikiDoc Sources